COMP <GO>
CVS vs KO // RSI-14 & 200D SMA MOMENTUM
CVS Health Corporation (NYSE) VS. Coca-Cola Company (The) (NYSE) • 15-METRIC TALLY: CVS 5
— KO 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: KO
LAST: $90.25 (-0.09%) • MKT CAP: $115.53B
rsi-technicals
47.5
LAST: $94.08 (+1.36%) • MKT CAP: $399.30B
rsi-technicals
62.5
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVS VS. KO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CVS | KO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.00% | 61.60% | -16.60 | KO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.60% | 25.30% | -22.70 | KO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.7x | 26.4x | -0.70 | CVS | /valuation <GO> |
| Free Cash Flow Yield | 6.76% | 1.33% | +5.43 | CVS | /fcf-yield <GO> |
| Operating Margin | 1.20% | 28.70% | -27.50 | KO | /operating-margins <GO> |
| Net Profit Margin | 0.40% | 27.30% | -26.90 | KO | /net-margins <GO> |
| Revenue Growth (YoY) | 7.80% | 1.90% | +5.90 | CVS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.94% | 2.20% | +0.74 | CVS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.31 | 6.84 | -4.53 | KO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | CVS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 47.5 | 62.5 | -14.99 | KO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.92 | -0.04 | KO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 60.7x | 28.4x | +32.30 | KO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $115.53B | $399.30B | -$283.77B | KO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CVS REV | KO REV | CVS GROSS % | KO GROSS % | CVS FCF | KO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $402.07B | $47.94B | 45.0% | 61.6% | $7.81B | $5.30B |
| FY 2024 | $372.81B | $47.06B | 44.7% | 61.1% | $6.33B | $4.74B |
| FY 2023 | $357.78B | $45.75B | 44.0% | 44.0% | -$2.67B | $9.54B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVS // BETA 0.88
KO // BETA 0.92